Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2021-10-28 Regulatory Filings
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Further Information on Proof of Concept Pilot Study 2 pages 189.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement providing additional information and clarification about a previously released pilot study on a cancer treatment. It includes statistical analysis details and sample size information but does not contain comprehensive financial data, regulatory certifications, or detailed financial reports. The document is relatively short (3655 characters) and focuses on clarifying scientific study results rather than financial or governance matters. It is not a full report like an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a regulatory filing or certification. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement providing additional disclosure requested by the ASX, without fitting into more specific categories such as capital updates, management changes, or legal proceedings.
2021-10-28 English
Appointment of Company Secretary 1 page 120.0KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement about the appointment of a new Company Secretary, detailing the individual's background and the outgoing secretary's new role. It does not contain financial data, regulatory certifications, or report publication information. It is an announcement related to changes in company management personnel, specifically at the company secretary level, which falls under Board/Management Information filings.
2021-10-28 English
Complete Regression of TNBC Tumours and Protective Immunity 10 pages 685.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement detailing the results of a Proof-of-Concept (PoC) pilot study for a cancer treatment drug INV043. It includes scientific findings, study design, and future research plans. The content is focused on research results and clinical potential rather than financial data or regulatory compliance. It is not a full financial report, earnings release, or management discussion. The document is lengthy (15,000 characters) and contains detailed study results and scientific data, but it is primarily an announcement of research progress and clinical trial results. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a corporate announcement related to research and development progress, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-10-27 English
Activities Report and Appendix 4C 7 pages 303.6KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement titled 'Activity Report and Cash Flow Report for the Quarter Ended 30 September 2021'. It includes detailed quarterly cash flow statements (Appendix 4C) and commentary on the company's cash position, R&D activities, financing activities, and future outlook. The presence of the Appendix 4C quarterly cash flow report, which is a regulatory requirement for Australian listed entities, confirms this is a quarterly financial report. The document contains substantive financial data and analysis for the quarter, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-10-20 English
Notice of Annual General Meeting/Proxy Form 24 pages 664.7KB
AGM Information Classification · 100% confidence The document is a detailed notice of the Annual General Meeting (AGM) for Invion Limited, including the date, time, virtual meeting details, agenda items such as receipt and consideration of accounts and reports, resolutions for election and re-election of directors, appointment of auditor, approval of remuneration report, and approval of share option issues. It also includes proxy voting instructions and other procedural information related to the AGM. The document does not contain financial statements or detailed financial analysis but serves as the official meeting notice and explanatory statement for shareholders to prepare for the AGM. Therefore, it fits the category of AGM Information (AGM-R).
2021-10-07 English
Grant of ASX Waiver 2 pages 157.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement titled 'Grant of Waiver' related to a waiver from ASX Listing Rule 10.13.5 concerning the issuance of options to directors. It discusses conditions for the issuance of Director Options and the timing of the Notice of Annual General Meeting. The document does not contain financial statements or detailed financial data, nor is it a full report. It is an announcement about a waiver related to director remuneration and the upcoming AGM notice. The document length is 3537 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-10-07 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.